Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Levoxiracetam by Nanjing Yoko Biomedical for Cognitive Impairment: Likelihood of Approval
Levoxiracetam is under clinical development by Nanjing Yoko Biomedical and currently in Phase III for Cognitive Impairment. According to GlobalData,...
Data Insights
Levoxiracetam by Nanjing Yoko Biomedical for Memory Impairment: Likelihood of Approval
Levoxiracetam is under clinical development by Nanjing Yoko Biomedical and currently in Phase III for Memory Impairment. According to GlobalData,...